Targeted therapies have significantly altered the landscape of oncology, for instance BRAF inhibitors in patients with BRAF-mutated melanoma [9] and ALK inhibitors in patients with ALK-rearranged lung cancer [10]. The gene discussed is BRAF; the disease is melanoma.